Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genomma Lab InternacionalB de CVMEX:LABB -0.23%66 Cyclically Adjusted Price-to-FCF is 6.92 as of Sep. 02, 2026, which is 59% below its 10-year median of 16.83. GuruFocus rates MEX:LABB with a GF Score™ of 66/100 and a GF Value™ of MXN17.40 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 331 Drug Manufacturers companies, Genomma Lab InternacionalB de CV ranks better than 92.45% on this metric.
The historical rank and industry rank for Genomma Lab InternacionalB de CV's Cyclically Adjusted Price-to-FCF or its related term are showing as below:
MEX:LABB'
s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 7.09 Med: 16.83 Max: 43.8
Current: 7.09
During the past years, Genomma Lab InternacionalB de CV's highest Cyclically Adjusted Price-to-FCF was 43.80. The lowest was 7.09. And the median was 16.83.
MEX:LABB's Cyclically Adjusted Price-to-FCF is ranked better than 92.45% of 331
companies
in the Drug Manufacturers industry
Industry Median: 28.22
vs MEX:LABB: 7.09
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Genomma Lab InternacionalB de CV's adjusted free cash flow per share data for the three months ended in Jun. 2026 was MXN0.269. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is MXN1.90 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Genomma Lab InternacionalB de CV (MEX:LABB) Cyclically Adjusted Price-to-FCF Explanation
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Genomma Lab InternacionalB de CV Cyclically Adjusted Price-to-FCF Related Terms
Genomma Lab InternacionalB de CV Cyclically Adjusted Price-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV Cyclically Adjusted Price-to-FCF Chart
MEX:LABB vs ZTS, UTHR, VTRS: Cyclically Adjusted Price-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Cyclically Adjusted Price-to-FCF falls into.
Genomma Lab InternacionalB de CV Cyclically Adjusted Price-to-FCF Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted Price-to-FCF of 6.92 mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a Cyclically Adjusted Price-to-FCF of 6.92 as of Sep. 02, 2026. Cyclically Adjusted Price-to-FCF Ratio is the ratio of share price to a company's inflation-adjusted FCF per share over a 10-year period. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is 59% below median its historical median of 16.83. Over the past decade, Genomma Lab InternacionalB de CV's Cyclically Adjusted Price-to-FCF has ranged from 7.09 to 43.80. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #25 out of 331 companies in the Drug Manufacturers industry, placing it in the top 7.6%.
Is Genomma Lab InternacionalB de CV's Cyclically Adjusted Price-to-FCF too high?
Genomma Lab InternacionalB de CV's current Cyclically Adjusted Price-to-FCF of 6.92 is 59% below median its 10-year median of 16.83. Over the past 10 years, this metric has ranged from a low of 7.09 to a high of 43.80. The Drug Manufacturers industry median Cyclically Adjusted Price-to-FCF is 28.22. Genomma Lab InternacionalB de CV's value of 6.92 is 75.5% below this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #25 out of 331 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Cyclically Adjusted Price-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #25 out of 331 companies for Cyclically Adjusted Price-to-FCF. This places Genomma Lab InternacionalB de CV in the top 8% of its industry — outperforming the majority of peers. The industry median Cyclically Adjusted Price-to-FCF is 28.22. Genomma Lab InternacionalB de CV's value of 6.92 is 75.5% below this benchmark. Historically, Genomma Lab InternacionalB de CV's own Cyclically Adjusted Price-to-FCF has ranged from 7.09 to 43.80 over the past decade. While the company's 10-year median is 16.83 vs. the industry median of 28.22, Genomma Lab InternacionalB de CV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Price-to-FCF for a Drug Manufacturers company?
The median Cyclically Adjusted Price-to-FCF among Drug Manufacturers companies is 28.22, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted Price-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted Price-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current Cyclically Adjusted Price-to-FCF of 6.92 is 75.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Price-to-FCF mean?
A high Cyclically Adjusted Price-to-FCF can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted Price-to-FCF Ratio is the ratio of share price to a company's inflation-adjusted FCF per share over a 10-year period. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted Price-to-FCF is 28.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current Cyclically Adjusted Price-to-FCF is 6.92, which is 59% below median its own 10-year median of 16.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.40, compared to a current price of MXN13.14 — trading 24.5% below its estimated fair value. The current Cyclically Adjusted Price-to-FCF is 6.92, which is 59% below median its 10-year median of 16.83 and 75.5% below the Drug Manufacturers industry median of 28.22. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Price-to-FCF calculated?
Cyclically Adjusted Price-to-FCF is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Cyclically Adjusted Price-to-FCF is 6.92 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN13.14 is trading 24.5% below its estimated GF Value™ of MXN17.40.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Cyclically Adjusted Price-to-FCF: 6.92 (59% below median its 10-year median of 16.83)
GF Value™: MXN17.40 vs. price of MXN13.14 (24.5% below fair value)
Industry Position: 75.5% below the Drug Manufacturers median (#25 of 331)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
Cyclically Adjusted Price-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
